Teprotumumab UpdateDec. 13, 2019
On Friday, Dec. 13th, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee met in Silver Spring, MD to discuss teprotumumab, a potential treatment for active thyroid eye disease.
The committee voted 12-0 Friday in favor of recommending approval of a biologics license application for teprotumumab. This is not the final approval, but is one step in the process. Key takeaways:
* Committee members expressed concern about the small study population (90 patients).
* Side effects were ...